- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05680870
The Possible Protective Role of Omeprazole Against Oxaliplatin Induced Neuropathy in Cancer Patients
The Possible Protective Role of Omeprazole Against Oxaliplatin Induced Neuropathy in Patients With Cancer Treated With Oxaliplatin-fluorouracil Chemotherapy Protocols
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Randomized controlled parallel study
Forty-six patients with pancreatic cancer or CRC who receive OXA 85mg/m2 in their protocols scheduled as a cycle every two consecutive weeks for 6 months to receive 12 cycles. Patients will be recruited from Clinical Oncology and Nuclear Medicine Department, Mansoura University Hospital, Mansoura, Egypt. The patients will be randomized using sealed envelope method into two groups:
According to the results of previous studies, the total number of subjects required detecting the effect of neuro-protective drugs in patients received chemotherapy with 5% significance and 80% power and attrition rate equal to 15% was 41 . In this context, during the current study, a total sample size 42 patients in both arms will be sufficient to provide a good power to detect the effect. Assuming that the attrition rate will be 10% the initial sample size will be 46 patients in both arms.
Assessment of patient adherence and evaluation of drug safety The medication will be provided on biweekly intervals and the participants adherence will be assessed through counting the pills and by medications refilling rate. Participants will also followed-up by telephone calls and through direct meetings during chemotherapy cycles to assess their adherence and report any drugs related adverse effects using adverse drug reactions reporting form the adverse effects will be also collected through patients' laboratory data and patient sheet. The patients will be asked about any adverse effects related to study medication. Patients will be considered non-adherent and excluded from the study if consumed less than 90% of study medication at any month of the study duration.
Statistical analysis - Statistical analysis will be done by the statistical software package version 25 . Data will be tested for normality using Kolmogorov-Smirnov and Shapiro wilk tests. Normally distributed data will be analyzed using paired and un-paired t-test. Non normally distributed data will be compared using Mann-Whitney U test. Also, Mann-Whitney U test will be used to compare non-parametric data between the two arms including the neuropathy grading and the Neurotoxicity-12(NTX-12) total scores. Categorical data will be computed by Chi-square test. - Fisher exact test will be used to analyze the reported adverse effects. - Correlation between variables will be analyzed by Pearson or spearman correlation what appropriate. - The significance level was set at p<0.05.
Study Type
Enrollment (Anticipated)
Phase
- Phase 3
Contacts and Locations
Study Contact
- Name: Sadek, Master
- Phone Number: 01007152209
- Email: Ayaa.sadeek@hotmail.com
Study Contact Backup
- Name: Aya M Sadek, Master
- Phone Number: 01018303331
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Recently diagnose cases with colorectal (CRC)and pancreatic cancers (males and females) ≥ 18 years old, and ≤ 65 years old.
- Patients who will scheduled to receive modified FOLFOX-4,6,7 (OXA, Leucovorin, and 5-fluorouracil) or mFOLFIRINOX (OXA, irinotecan,leucovorin, and 5-Fluorouracil) for 12 cycles.
- Patients with performance status 0-2 according to Eastern Cooperative Oncology Group (ECOG) Score.
Exclusion Criteria:
- Evidence of pre-existing peripheral neuropathy resulting from another reason (documented patients with brain tumor, brain trauma, seizures or any other neuropathic disorder).
- CRC patients receiving protocols containing capecitabine.
- Diabetic patients.
- Documented Patients with lupus (SLE), or any other autoimmune disease.
- Documented Patients with osteoporosis or fractures.
- Prior exposure to neurotoxic chemotherapy for at least 6 months prior to the study.
- Concomitant use of other neuroprotective medications (gabapentin, lamotrigine, phenytoin, tricyclic antidepressants, etc.,).
- Patients taking medications that omeprazole can interact with or affect their metabolism, such as (digoxin, ketoconazole, methotrexate, clopidogrel, marevan, etc.,).
- Pregnant and breastfeeding women.
- Patients with abnormal renal function (S.cr > 1.5 mg/dl or crcl < 45 ml/min).
- Patients with liver diseases (serum bilirubin > 1.5 mg/dl / Alanine transaminase, Aspartate transaminase > 2-4 ULN).
- Smokers or documented patients with condition associated with oxidative stress.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
No Intervention: Control group
Control grp will not receive omeprazole .
They will receive chemotherapy protocols only
|
|
Experimental: Intervention group
Intervention group will receive omeprazole plus chemotherapy protocols
|
Omeprazole 40 mg 3 times daily for 5 days ..to start 2 days before chemotherapy cycles
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Acute peripheral neuropathy
Time Frame: After the first intervention by 2 weeks of the first chemotherapy cycle ( each cycle is two days every two weeks), and through the study average for six months
|
the percentage of patients with acute peripheral sensory neuropathy grade ≥ 2 and the variation of both 12-item neurotoxicity questionnaire (Ntx-12) total score and pain rating scale score
|
After the first intervention by 2 weeks of the first chemotherapy cycle ( each cycle is two days every two weeks), and through the study average for six months
|
Chronic peripheral neuropathy
Time Frame: After the end of 12 chemotherapy cycles ( after six months of interventions)
|
Percentage of patients who have developed chronic peripheral neuropathy grade ≥ 2 after the end of 12 cycles and the variation of both NTX-12 total score and pain rating scale
|
After the end of 12 chemotherapy cycles ( after six months of interventions)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Malonaldehyde
Time Frame: After 3 months of treatment
|
Changes in malonaldehyde level
|
After 3 months of treatment
|
Neurotensin
Time Frame: After 3 months of treatment
|
Changes in neurotensin level
|
After 3 months of treatment
|
OCT
Time Frame: After 3 months of treatment
|
Changes in OCT level
|
After 3 months of treatment
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Sahar K Hegazy, Professor, Professor of clinical pharmacy , faculty of pharmacy, Tanta university
Study record dates
Study Major Dates
Study Start (Anticipated)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- MS.22.12.2244.R1
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Chemotherapy Induced Peripheral Neuropathy
-
Academisch Medisch Centrum - Universiteit van Amsterdam...Leiden University Medical Center; Reinier de GraafRecruitingChemotherapy-induced Peripheral Neuropathy | CIPN - Chemotherapy-Induced Peripheral Neuropathy | Qutenza | DuloxetineNetherlands
-
Arash Asher, MDVoxxLifeRecruitingNeuropathy | Chemotherapy-induced Peripheral Neuropathy | Neuropathy;PeripheralUnited States
-
Institut Cancerologie de l'OuestGrünenthal GmbHNot yet recruitingChemotherapy-induced Peripheral Neuropathy
-
Odense University HospitalAarhus University Hospital; University of Southern Denmark; Sygehus LillebaeltRecruitingChemotherapy-induced Peripheral NeuropathyDenmark
-
WinSanTor, IncRecruitingChemotherapy-induced Peripheral NeuropathyUnited States
-
Veloxis PharmaceuticalsRecruitingChemotherapy-induced Peripheral NeuropathyUnited States, Japan
-
National University Hospital, SingaporePaxman Coolers Ltd.; The N.1 Institute for Health, National University of SingaporeRecruitingChemotherapy-induced Peripheral NeuropathySingapore
-
University of Rochester NCORP Research BaseNational Cancer Institute (NCI)RecruitingChemotherapy-Induced Peripheral NeuropathyUnited States
-
Donna Hammond, PhDActive, not recruitingChemotherapy-induced Peripheral NeuropathyUnited States
-
University of Rochester NCORP Research BaseNational Cancer Institute (NCI)CompletedEffects of Transcutaneous Electrical Nerve Stimulation on Chemotherapy-Induced Peripheral NeuropathyChemotherapy-Induced Peripheral NeuropathyUnited States
Clinical Trials on Omeprazole
-
Damascus HospitalWithdrawnPeptic Ulcer Hemorrhage | Marginal Ulcer | Gastroduodenal UlcerSyrian Arab Republic
-
MetroHealth Medical CenterCompleted
-
University of LouisvilleBausch Health Americas, Inc.CompletedGastroesophageal Reflux Disease | GastroparesisUnited States
-
BayerBausch Health Americas, Inc.CompletedGastric Acid | Human Experimentation
-
BayerBausch Health Americas, Inc.CompletedGastric Acid | Human Experimentation
-
Aboca Spa Societa' AgricolaUniversity of Roma La Sapienza; Doppel Farmaceutici; BMR GenomicsCompleted
-
Yvonne RomeroBausch Health Americas, Inc.CompletedErosive EsophagitisUnited States
-
Nekkar Lab SrlOpera CRO, a TIGERMED Group CompanyRecruitingGastroesophageal Reflux Disease (GERD)Italy, Romania